most well known [1%:40 years of age) should undergo adequate cardiac evaluation prior to administration; if the cardiac evaluation is satisfactory, first dose should be given in the healthcare provider's office (consider ECG monitoring). All patients should undergo periodic evaluation of cardiovascular status during treatment. Hepatic impairment: Use with caution in patients with hepatic impairment. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction is recommended. Renal impairment: Use with caution in patients with moderate-to-severe renal failure. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction is recommended for severe renal impairment. Concurrent drug therapy issues: Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce almotriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases. Other warnings/precautions: Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic migraine, or basilar migraine. If a patient does not respond to the first dose, the diagnosis of acute migraine should be reconsidered. Pregnancy Risk Factor C Pregnancy Considerations Adverse events were observed in animal reproduction studies. Information related to almotriptan use in pregnancy is limited (Källén, 2011; Nezvalová-Henriksen, 2010; Nezvalová-Henriksen, 2012). Until additional information is available, other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva, 2012; MacGregor, 2012; Williams, 2012). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience fatigue or dry mouth. Have patient report immediately to prescriber severe headache, severe dizziness, passing out, constipation, diarrhea, severe nausea, severe vomiting, severe abdominal pain, bloody diarrhea, burning or numbness feeling, weight loss, leg cramps, feeling of heaviness in legs, leg pain, sensation of cold, burning or aching pain in feet or toes, shortness of breath, vision changes, blindness, abnormal heartbeat, signs of serotonin syndrome (dizziness, severe headache, agitation, hallucinations, tachycardia, abnormal heartbeat, flushing, tremors, sweating a lot, change in balance, severe nausea, or severe diarrhea), signs of a heart attack (angina; pain in arms, back, neck, jaw, or abdomen; shortness of breath; cold sweats; severe dizziness; passing out; or severe nausea or vomiting), or signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about almotriptan Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Images Drug Interactions Support Group Pricing & Coupons En Español 29 Reviews Add your own review/rating Drug class: antimigraine agents Consumer resources Almotriptan Almotriptan (Advanced Reading) Professional resources Almotriptan Malate (AHFS Monograph) Almotriptan (FDA) Other brands: Axert Related treatment guides Migraine] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Almotriptan Rating 29 User Reviews 9.0 /10 29 User Reviews 9.0 Rate it! Manufacturers Mylan Pharmaceuticals Inc. Teva Pharmaceuticals USA, Inc. Drug Class Antimigraine agents Related Drugs antimigraine agents sumatriptan , Imitrex , rizatriptan , Maxalt , Relpax , Zomig Migraine diclofenac , sumatriptan , metoclopramide , Imitrex , Reglan , rizatriptan , Maxalt , Excedrin , Butalbital Compound , cyproheptadine , Botox , Relpax , Fiorinal , Excedrin Migraine , Zomig , naratriptan , aspirin / butalbital / caffeine , zolmitriptan , Cambia , acetaminophen / aspirin / caffeine , eletriptan , Maxalt-MLT , onabotulinumtoxinA , ergotamine , More... Almotriptan Images Almotriptan systemic 6.25 mg (base) (93 A1) View all images most beneficial
to confess Almotriptan probably the greatest
EmoticonEmoticon